FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number: 3235-								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Herde Kevin					2. Issuer Name and Ticker or Trading Symbol MARAVAI LIFESCIENCES HOLDINGS, INC. [MRVI]									(Check	tionship of R all applicabl Director Officer (q	le)	erson(s) to Issuer 10% Ov Other (s	· I
(Last) (First) (Middle) C/O MARAVAI LIFESCIENCES HOLDINGS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 04/29/2022								X	below) Chief Finance		ncial (below)		
10770 WATERIDGE CIRCLE, SUITE 200						4. If Amendment, Date of Original Filed (Month/Day/Year) 06/27/2022								6. Indiv	_ · · · · ·				
(Street) SAN DIEGO CA 92121															Form filed	d by More	than O	ne Reportin	g Person
(City)	(State)	(Zi _l	p)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				nth/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)					ies Acquired (A) or Of (D) (Instr. 3, 4 an			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Class A Common Stock 04/2					29/2022				A ⁽¹⁾	V	427		A	\$22.95	20,816			D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3) 2. Conversion Date Execution Date (Month/Day/Year) 3. Transaction Date Execution Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. Deemed Execution Date (Month/Day/Year)			Code (Instr.			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		te	7. Title and Amo Securities Unde Derivative Secu (Instr. 3 and 4)		derlying curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code V		(A)	(D)	Date Exercis		Expiration Date	Title		Amount or Number of Shares		Transaction(s) (Instr. 4)			

Explanation of Responses:

1. Amended to note that this is a voluntary filing. The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 427 shares of Class A Common Stock was exempt pursuant to Rule 16b-3.

Remarks:

/s/ Kurt Oreshack, by power of 06/27/2022 attorney for Kevin Herde

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.